TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bolus of Saline in Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Acute ischemic stroke in the territory of the anterior, middle, or posterior cerebral artery territory on either side of the brain~* Study intervention can be initiated within 96 hours of symptom onset~* Willingness and ability to sign informed consent by patient or legally acceptable surrogate decision-maker~Exclusion Criteria:~* Infarct limited to the brainstem and/or cerebellum with no involvement of the cerebral hemispheres~* Bi-hemispheric infarction or acute infarct in the contra-lateral hemisphere within the past 30 days~* Symptoms of active congestive heart failure (dyspnea, orthopnea, increased oxygen requirement)~* Exacerbation of congestive heart failure, requiring hospitalization, within the past 30 days or severe systolic dysfunction with a known ejection fraction \<20%~* End stage renal disease requiring hemodialysis or a creatinine clearance \<20 ml/min/1.73 m2~* Hemicraniectomy or other skull defect that would interfere with monitoring~* Pregnant women are excluded. Women of child-bearing age must have a negative pregnancy test prior to enrollment~* Participation in another clinical trial~* Any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: EXPERIMENTAL): intravenous administration of 500cc of 0.9% NaCl over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with type 1 diabetes (T1DM )for at least one year~* patients aged 12-27 years~* patients using MiniMed 780G AHCL system (Medtronic, Northridge, CA, USA) at least 6 months before the study~* patients with minimum daily insulin requirement of more than 8 units~* patients willingness and ability to adhere to the study protocol, access to the internet and a computer system that met requirements for uploading the study pump data.~Exclusion Criteria:~* patients with any microvascular or macrovascular complications~* pregnancy, lactation~* patients who had a point-of-care screening HbA1c \>10.0% (86 mmol/mol)~* patients with hypoglycemic unawareness or recurrent severe hypoglycemic episode in the last 6 months prior to recruitment~* patients with recurrent DKA (more than 2 episodes in the previous 6 months).~* patients with any chronic medical condition, current use of medications (other than insulin) that are known to affect blood glucose level.~* patients who had prior adverse reactions to the adjunctive agent

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 27 Years
- Healthy Volunteers: f

Study Arms:
- Dipeptidyl peptidase-4 inhibitors (Type: ACTIVE_COMPARATOR): Dipeptidyl peptidase-4 inhibitors with Iftar meal
- Control group (Type: NO_INTERVENTION): No Dipeptidyl peptidase-4 inhibitors intake with Iftar meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of community-acquired pneumonia as follows: clinical signs and symptoms of a lower respiratory tract infection and chest-x-ray findings consistent with pneumonia within 24 hours before entry into the study~* At least one of the following: abnormal temperature (high or low) or abnormal white blood cell count~* Previous antibiotic treatment \<= 24 hours or, if the duration of treatment was \>= 72 hours and that therapy failed based on at least 2 of the following: fever within 12 hours of entry into the study, chest x-ray findings have worsened compared to the initial chest-x-ray, white blood cell count is significantly increased, respiratory rate higher than at the start of treatment and \>= 20 breaths per minute or need for supplemental oxygen if not previously needed~* Patients whose infection is acquired in the community or, if in a nursing home, who had been living there \< 14 days~* Fine Class (rating scale used to assess patients' overall condition which includes information such as age, gender, other diseases, physical examination and laboratory findings) score \<= 130 upon admission (patients with Fine Class scores \> 70 but \< = 130 must initially be hospitalized~* Patients with scores of \<= 70 may be treated as outpatients or hospitalized at the discretion of the investigator)~Exclusion Criteria:~* Pneumonia known or suspected to be due to a bacteria resistant to levofloxacin~* Previous allergic or serious reaction to or failed therapy with levofloxacin or similar drugs~* Life expectancy \< 72 hours~* Hospitalized within 2 weeks before entry in the study or within 1 month before entry in the study if treated with antibiotics~* Pneumonia acquired in a hospital~* Cystic fibrosis or other lung disorders~* Receiving chronic steroid treatment~* Received assistance from a machine to breathe within the previous month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult hospitalized patients with a diagnosis of CAP (based on local medical practice) and decision taken by the investigator to treat with moxifloxacin and to start treatment with intravenous administration. The local moxifloxacin product information must be considered.~Exclusion Criteria:~* Contraindications stated in the local moxifloxacin product information; warnings and precautions must be considered.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid vs. Quixil - Reducing Blood Loss in Joint Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are to undergo elective hip or knee joint replacement~* Must be cemented arthroplasty~* Must be primary arthroplasty~Exclusion Criteria:~* Uncemented arthroplasty.~* Revision arthroplasty.~* Patients on anticoagulant (warfarin, low molecular weight heparin) or other medication known to affect clotting (except aspirin, which is to be given as part of standard DVT prophylaxis in all cases).~* Other drugs that may affect the activity of the drugs under investigation.~* Allergy to asprin (all patients to receive 150mg aspirin as standard DVT prophylaxis for 6 weeks).~* Patients with known coagulopathy (APTT or PT outside normal range pre-operatively).~* Previous reaction or ethical/religious objection to receiving blood products (Quixil contains a derivative of human blood).~* Pregnancy or breastfeeding.~* Patients who have a past medical history of thrombo-embolism at any time.~* Patients who need intravenous fluid administration for greater than 24 hours following operation.~* Patients who need allogenic blood transfusion within study period.~* Jehovah's Witnesses, or any other group of patients with ethical objections to receiving blood products.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stannous Fluoride and Gingivitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years of age or older;~* Provide written informed consent and receive a signed copy of consent;~* Agree to delay any elective dentistry, including dental prophylaxis, and to report any non-study dentistry received during the course of this study;~* Agree not to participate in any other oral care studies for the duration of this study;~* Agree to refrain from any form of non-specified oral hygiene during the treatment periods, including but not limited to the use of products such as floss or whitening products;~* Agree to return for all scheduled visits and follow study procedures;~* Have at least 16 natural teeth;~* Be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study.~For Unhealthy Group:~* Have at least 20 bleeding sites (sites with a score of 1 or 2 on the Screening GBI exam); and~* Have a minimum of 3 sampling sites with bleeding and pocket depth \>/=3mm but not deeper than 4mm at the Screening visit.~For Healthy Group:~* Have a maximum of 3 bleeding sites (sites with a score of 1 or 2 on the Screening GBI exam); and~* No pockets deeper than 2mm.~Exclusion Criteria:~* Self-reported pregnancy or the intent to become pregnant anytime during the course of the study;~* Inability to comply with study procedures;~* Rampant caries, open or untreated caries, or advanced periodontitis requiring prompt treatment;~* Severe periodontal disease, including but not limited to purulent exudate, generalized mobility, and/or severe recession;~* Fixed orthodontic appliances or attachments for aligner treatment;~* Having had a dental prophylaxis within 2 weeks of plaque sampling visits;~* Having taken antibiotics or used anti-gingivitis/anti-bacterial oral care products such as chlorhexidine or Listerine within 2 weeks of plaque sampling visits;~* Needing an antibiotic prophylaxis prior to dental visits;~* Presenting with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study; or~* Having any condition or disease, as determined by the Investigator/Designee which could be expected to interfere with examination procedures or with the subject's safe completion of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Group (Type: ACTIVE_COMPARATOR): Subjects without gingivitis (\</= 3 bleeding sites) will use stannous fluoride toothpaste
- Unhealthy Group (Type: ACTIVE_COMPARATOR): Subjects with gingivitis (\>/= bleeding 20 sites) will use stannous fluoride toothpaste

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of RA (2010 American College of Rheumatology \[ACR\]/European League Against Rheumatism \[EULAR\] criteria) and are ACR functional class I-III.~* Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥ 6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both screening and Day 1.~* Limited or no prior treatment with MTX~Key Exclusion Criteria:~* Previous treatment with any janus kinase (JAK) inhibitor~* Previous therapy for longer than 3 months with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) other than MTX or hydroxychloroquine~* Use of any licensed or investigational biologic disease-modifying antirheumatic drugs (DMARDs)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg + MTX (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
- Filgotinib 100 mg + MTX (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
- Filgotinib 200 mg Monotherapy (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
- MTX Monotherapy (Type: ACTIVE_COMPARATOR): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active RA in spite of stable dose of MTX~Exclusion Criteria:~* Having received infliximab in the past~* Having a history of serious infection which caused hospitalization within 6 months before the registration~* Having an active tuberculosis~* Having a complication or a history of malignancy within 5 years before the registration

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 3 mg/kg (Type: EXPERIMENTAL): None
- TA-650 6 mg/kg (Type: EXPERIMENTAL): None
- TA-650 10 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females 2 years and older~* Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka~* Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)~* Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1~* All female subjects of childbearing potential must use acceptable methods of contraception from the Screening Visit continuously until 30 days after stopping study drug~Exclusion Criteria:~* As determined by the study doctor, a medical history that may interfere with study objectives~* Unstable AD or any consistent requirement for high potency topical corticosteroids~* History of use of biologic therapy (including intravenous immunoglobulin)~* Recent or anticipated concomitant use of systemic or topical therapies that might alter the course of AD~* Recent or current participation in another research study~* Females who are breastfeeding, pregnant, or with plans to get pregnant during the participation in the study~* Participation in a previous AN2728 clinical trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AN2728 Topical Ointment, 2% (Type: EXPERIMENTAL): AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
- Matching vehicle control (Type: PLACEBO_COMPARATOR): Matching vehicle control, applied twice daily for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject, and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written Informed Consent.~* Subject was to be 6-11 years of age, of either sex and of any race.~* If female, subject was to be premenarcheal.~* Subject was to be willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment.~* Subject was to be free of any clinically significant disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections.~* Subject was to have understood and been able to adhere to the dosing and visit schedules.~Exclusion Criteria:~* If female, subject who was pregnant, intended to become pregnant during the study or nursing.~* Subject had used any investigational product within 30 days prior to enrollment.~* Subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough.~* Subject had a current medical condition that, in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.).~* Subject was participating in any other clinical study(ies).~* Subject was part of the staff or a family member of the staff personnel directly involved with this study.~* Subject was allergic to or has sensitivity to the study drug or its excipients.~* Subject had a history of allergic reaction to prescription and/or OTC medications and/or food products.~* Subject had used any antihistamines within 24 hours prior to tasting as outlined in Section 9.4.7.~* Subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- RediTab/Zyrtec (Type: ACTIVE_COMPARATOR): Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
- Zyrtec/RediTab (Type: ACTIVE_COMPARATOR): Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The BRAIN App: Building Relationships Using Artificial Intelligence and Nostalgia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
PWD Inclusion Criteria:~* diagnosed with dementia (any type)~* resident in ALF or NH~* 65+ years old~* read and speak English~* exhibit at least one responsive behavior on the NPI-NH or score below maximum score on the DEMQOL~PWD Exclusion Criteria:~* bed-confined~* completely unable to communicate verbally~* have serious visual or hearing impairments~* show signs of rapid decline or over the last six months~Staff and Family Member Inclusion Criteria~* 18+ years old~* speak and read English~Staff and Family Member Exclusion Criteria~-n/a

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): BRAIN Intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 5 \< UHDRS \< 50~* Age \> 18 years~* Ability to undergo MR scanning~* Covered by french social security~Exclusion Criteria:~* Evidence of psychiatric disorder~* Attendant neurological disorder~* Contraindications to MRI (claustrophobia, metallic or material implants)~* Severe head injury~* Unable to understand the protocol~* Pregnancy~* Failure to give informed consent~* Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)~* Unwillingness to be informed in case of abnormal MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triheptanoin 1g/kg/day (Type: EXPERIMENTAL): All patients received Triheptanoin oil at 1g/kg/day during 1 month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients Have Type 2 Diabetes Mellitus~* On Diet/Exercise Therapy And Pioglitazone As Monotherapy~Exclusion Criteria:~* Patients Have Type 1 Diabetes Mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK0431 + pioglitazone
- 2 (Type: PLACEBO_COMPARATOR): Placebo/MK0431 + pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete